Pharmacia Vestra
Executive Summary
FDA has agreed to hold an advisory committee review for the antidepressant Vestra (reboxetine) after issuing a "not approvable" letter, Pharmacia says. The NDA for the selective norepinephrine reuptake inhibitor was submitted in April 1998 and was deemed "approvable" in July 1999 and again in February 2000